Celgene acquires late-stage product for Crohn's disease and other GI disorders
Celgene announced a global license agreement with Nogra Pharma, a private pharmaceutical company based in Dublin, Ireland, to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease and other indications. April 24, 2014